Esperance Pharmaceuticals

company

About

Esperance Pharmaceuticals develops anticancer drugs that kill cancer cells without harming normal cells.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$7.50M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2006
Number Of Employee
11 - 50
Operating Status
Active

Esperance Pharmaceuticals is developing a new class of targeted anticancer drugs that selectively kill cancer cells without harming normal cells. Targeting occurs through binding to specific receptors on the cell's surface. The drugs kill even those cells known to be resistant to chemotherapeutic drugs.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$19.70M
Esperance Pharmaceuticals has raised a total of $19.70M in funding over 2 rounds. Their latest funding was raised on Jun 1, 2011 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 1, 2011 Series B $7.50M 3 Sanofi Detail
Nov 24, 2008 Series A $3.20M 1 Detail
Oct 31, 2006 Series A $9M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
3
Esperance Pharmaceuticals is funded by 3 investors. Sanofi and Advantage Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Sanofi Yes Series B
Advantage Capital Series B
Themelios Ventures Series B